# SUPPLEMENTAL MATERIAL

Supplemental Methods	. 2
Supplemental Tables	. 3
Supplemental Table 1. Analytical variability of the assays, expressed as between-batch	
coefficient of variation (CV%) of vitamin D metabolites	. 3
Supplemental Table 2. Characteristics of the vitamin D <sub>3</sub> supplemented cohort	. 4
Supplemental Table 3. Sensitivity analysis of associations of eGFR and race with 25(OH)D	
clearance in the full study population versus excluding two outlier participants	. 6
Supplemental Figures	. 7
Supplemental Figure 1. Participant flow in the Clearance of 25-hydroxyvitamin D in Chronic	;
Kidney Disease Study	. 7
Supplemental Figure 2. Relationship between eGFR with 25-hydroxyvitamin D clearance by	
race	. 8
Supplemental Figure 3. Linear regression depicting the relationship of 25-hydroxyvitamin D	
response to vitamin $D_3$ supplementation with mean 25-hydroxyvitamin D clearance in the	
vitamin D <sub>3</sub> supplemented cohort	. 9

#### SUPPLEMENTAL METHODS

#### **Deuterated 25-hydroxyvitamin D3**

Deuterated 25-hydroxyvitamin  $D_3$  was specially designed for this study and manufactured at Sigma-Aldrich ISOTEC, Stable Isotope Division (Miamisburg, OH). It was formulated as single use vials in 10% ethanol and 60% propylene glycol at SRI International (Menlo Park, CA), where stability testing verified concentration within 10% of target and suitability for human injection according to GCP and FDA standards.

#### Covariates

Diabetes was defined by self-report, fasting blood glucose > 126 mg/dL, non-fasting blood glucose > 200 mg/dL, hemoglobin A1c  $\ge$  6.5% or use of glucose-lowering medications. Blood pressure was measured three times 5 minutes apart on an automated sphygmomanometer, and were averaged for analysis. Hypertension was defined by self-report, systolic blood pressure  $\ge$  140 mmHg, diastolic blood pressure  $\ge$  90 mmHg, or use of antihypertensive medications. Current medication and supplement use were ascertained from pill bottles and computerized medication lists. Height and weight were measured during the screening visit. Estimated blood volume (EBV) was calculated using the Nadler equation: for men, EBV = (0.3669 x (height in meters)<sup>3</sup>) + (0.03219 x weight in kilograms) + 0.641; for women, EBV = (0.3561 x (height in meters)<sup>3</sup>) + (0.03308 x weight in kilograms) + 0.1833.

### SUPPLEMENTAL TABLES

### Supplemental Table 1. Analytical variability of the assays, expressed as between-batch

Metabolite	<b>CV</b> (%)	Concentration Range Tested
25(OH)D <sub>2</sub>	3.45% - 15.23%	1.33-40.82 ng/mL
25(OH)D <sub>3</sub>	1.72% - 3.30%	14.94 – 41.25 ng/mL
1,25(OH) <sub>2</sub> D <sub>2</sub>	5.04% - 7.65%	1.00 – 52.60 pg/mL
1,25(OH) <sub>2</sub> D <sub>3</sub>	3.00% - 5.40%	27.31 – 82.69 pg/mL
24,25(OH) <sub>2</sub> D <sub>3</sub>	1.96% - 6.23%	1.15 – 3.44 ng/mL
d-25(OH)D <sub>3</sub>	2.71% - 24.86%	0.76-7.81 ng/mL
d-24,25(OH) <sub>2</sub> D <sub>3</sub>	16.9% - 76.4%	0.02-0.20  ng/mL

coefficient of variation (CV%) of vitamin D metabolites

25(OH)D = 25-hydroxyvitamin D;  $1,25(OH)_2D = 1,25$ -dihydroxyvitamin D;  $24,25(OH)_2D_3 = 1,25$ -dihydroxyvi

24,25-dihydroxyvitamin D<sub>3</sub>; d-25(OH)D<sub>3</sub> = deuterated 25-hydroxyvitamin D<sub>3</sub>; d-24,25(OH)<sub>2</sub>D<sub>3</sub>

= deuterated 24,25-dihydroxyvitamin D<sub>3</sub>

	Healthy controls $(n = 10)$	CKD (n = 8)
Age (years), mean (SD)	$60 \pm 6$	$69\pm7$
Female, n (%)	4 (40%)	2 (25%)
Race, n (%)		
White	4 (40%)	4 (50%)
Black	6 (60%)	4 (50%)
Hypertension, n (%)	3 (30%)	6 (75%)
Diabetes, n (%)	1 (10%)	5 (63%)
Ever smoker, n (%)	5 (50%)	2 (25%)
RAAS-I use, n (%)	1 (10%)	5 (63%)
Statin use, n (%)	1 (10%)	5 (63%)
Systolic BP (mmHg), mean (SD)	118 (9)	118 (26)
BMI (kg/m <sup>2</sup> ), mean (SD)	27.4 (3.7)	29.7 (5.0)
EBV (L), mean (SD)	5.0 (0.7)	5.6 (0.9)
Total 25(OH)D (ng/mL), mean (SD)		
Baseline	17 (6)	26 (5)
After vitamin D <sub>3</sub> supplementation	33 (6)	40 (10)
PTH (pg/mL), median (IQR)		
Baseline	62 (45, 66)	102 (77, 165)
After vitamin D <sub>3</sub> supplementation	41 (34, 54)	79 (62, 151)
FGF-23 (pg/mL), median (IQR)		
Baseline	55 (51, 67)	134 (105, 164)
After vitamin D <sub>3</sub> supplementation	54 (50, 65)	140 (85, 183)
Calcium (mg/dL), mean (SD)		
Baseline	9.2 (0.3)	9.2 (0.3)
After vitamin D <sub>3</sub> supplementation	9.3 (0.2)	9.2 (0.3)
VDBG (µg/mL), mean (SD)	191 (26)	205 (34)
eGFR (ml/min/1.73m <sup>2</sup> ), mean (SD)	89 (12)	37 (13)
Urine albumin/creatinine (mg/g), median (IQR)	0 (0, 28)	96 (22, 253)

## Supplemental Table 2. Characteristics of the vitamin D<sub>3</sub> supplemented cohort

eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease; RAAS-I = renin-

angiotensin-aldosterone inhibitor; BP = blood pressure; BMI = body mass index; EBV =

estimated blood volume; 25(OH)D = 25-hydroxyvitamin D; PTH = parathyroid hormone; FGF-23 = fibroblast growth factor-23; VDBG = vitamin D binding globulin; SD = standard deviation; IQR = interquartile range

	β coefficient (95% CI) of 25(OH)D clearance (mL/day) per 10		
	mL/min/1.73m <sup>2</sup> eGFR lower		
	Outliers excluded $(n = 85)$	Full study population $(n = 87)$	
Unadjusted model			
All participants	-14 (-19, -8)	-13 (-20, -6)	
Among black participants	-20 (-29, -12)	-20 (-29, -12)	
Among white participants	-10 (-16, -4)	-10 (-19, 0.2)	
Adjusted model <sup>*</sup>			
All participants	-17 (-21, -12)	-17 (-23, -11)	
Among black participants	-21 (-30, -12)	-21 (-30, -12)	
Among white participants	-15 (-20, -10)	-16 (-23, -8)	

Supplemental Table 3. Sensitivity analysis of associations of eGFR and race with 25(OH)D

	Outliers excluded $(n = 85)$	Full study population $(n = 87)$	
Unadjusted model			
All participants	-14 (-19, -8)	-13 (-20, -6)	
Among black participants	-20 (-29, -12)	-20 (-29, -12)	
Among white participants	-10 (-16, -4)	-10 (-19, 0.2)	
Adjusted model*			
All participants	-17 (-21, -12)	-17 (-23, -11)	
Among black participants	-21 (-30, -12)	-21 (-30, -12)	
Among white participants	-15 (-20, -10)	-16 (-23, -8)	
	$\beta$ coefficient (95% CI) of 25(OH)D clearance (mL/day) comparing black with white race		
	Outliers excluded $(n = 85)$	Full study population $(n = 87)$	
Unadjusted model			
All participants	41 (-1, 83)	23 (-35, 80)	
Among healthy controls	92 (41, 144)	77 (6, 148)	

-11(-55, 34)

clearance in the full study population versus excluding two outlier participants

71 (16, 125) 26 (-32, 84) Among healthy controls

eGFR = estimated glomerular filtration rate; 25(OH)D = 25-hydroxyvitamin D

22 (-12, 56)


\*Adjusted for age, sex, race and estimated blood volume

\*\*Additionally adjusted for eGFR

Adjusted model<sup>\*\*</sup>

All participants


### SUPPLEMENTAL FIGURES




Supplemental Figure 1. Participant flow in the Clearance of 25-hydroxyvitamin D in Chronic

Kidney Disease Study. 25(OH)D = 25-hydroxyvitamin D; d-25(OH)D<sub>3</sub> = deuterated 25-

hydroxyvitamin D<sub>3</sub>



**Supplemental Figure 2.** Relationship between eGFR with 25-hydroxyvitamin D clearance by race. eGFR = estimated glomerular filtration rate; 25(OH)D = 25-hydroxyvitamin D



Supplemental Figure 3. Linear regression depicting the relationship of 25-hydroxyvitamin D response to vitamin D<sub>3</sub> supplementation with mean 25-hydroxyvitamin D clearance in the vitamin D<sub>3</sub> supplemented cohort. 25(OH)D = 25-hydroxyvitamin D; CKD = chronic kidney disease

\*Total 25(OH)D after vitamin  $D_3$  supplementation – total 25(OH)D before vitamin  $D_3$  supplementation

\*\*From the parent study and vitamin D<sub>3</sub> supplementation sub-study